XTL Biopharmaceuticals announced that a patent has been issued covering the Europe Union for its leading drug candidate, hCDR1 (edratide), a potential treatment for systemic lupus erythematosus (SLE). The European Patent Office issue (EP1594434) is titled “Parenteral Formulations of Peptides for the Treatment of Systemic Lupus Erythematosus,” and covers formulations…
XTL Biopharmaceuticals has filed a new U.S. patent application to protect doses of hCDR1 lower than 0.5 mg per week to treat systemic lupus erythematosus (SLE). XTL is a clinical-stage biotech that develops products for the treatment of autoimmune diseases like lupus. The company’s lead drug candidate, hCDR1 has…
XTL Biopharmaceuticals has completed the design of a Phase 2 clinical trial investigating its drug candidate hCDR1 for systemic lupus erythematosus (SLE). The planned international study will be launched this year after the company files its investigational new drug (IND) paperwork with the U.S. FDA. XTL’s lead product hCDR1 is a…
Israel-based XTL Biopharmaceuticals, a clinical stage biotech company that focuses on the development of new drugs for the treatment of autoimmune diseases, has announced that its lead drug candidate, hCDR1, has been granted a patent by the Hungarian Intellectual Property Office. The patent, “Synthetic Human Peptides and Pharmaceutical Compositions Comprising…
XTL Biopharmaceuticals Ltd. announced it accepted an invitation to join Lupus Foundation of America (LFA)’s Corporate Advisory Council (CAC). XTL is a clinical-stage biotech dedicated to developing pharmaceutical products to treat autoimmune diseases such as lupus. The biotech’s lead drug candidate, hCDR1, is a top-quality clinical asset for the…
XTL Biopharmaceuticals has announced it has submitted the full protocol for its advanced stage clinical trial of hCDR1 in the treatment of systemic lupus erythematosus (SLE, commonly referred to as lupus) to Yeda Research and Development Company in Israel. According to the Phase II clinical study titled “Safety…